Advances in Virology / 2020 / Article / Fig 1

Research Article

HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007)

Figure 1

Antiviral activity of SRI-32007 against HBV genotype D in HepG2.2.2.15 cells. HepG2.2.2.15 cells in 96 wells were treated with different concentrations of SRI-32007 for six days followed by measurement of virus associated DNA in the culture supernatants by HBV specific qPCR. HBV DNA and HBe Ag levels in the treated samples and cell viability normalized to the untreated samples (average ± standard deviation from triplicate samples) are shown in the figure.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.